Teva Pharmaceutical Finance Netherlands IV BV

Deals

C/PSectorStatusDeal NameParentLeadsRegionDate
IGC
HLTH
PRCD
TEVA 2016-3 (CHF 1,000m)Teva PharmaceuticalsEMEA
Jul 21, 2016
CCYSIZE (M)TNRMTYRNKMOSPFITYPEBNCHIPTGDNCSPRDCPNNICPRICE
OVD642.0007Apr-08-Zmm2LLL-PwfozFrnir-0.15% i86.30.13%-522.00000
EEN828.0007Jul-00Fg. KgsalugaaPii2YYY-SqfvcAetvm-NZ+110 e1050.50%-795.52200
BIB312.0006Apr-94Sx. PblximxxoQll2III-FzhjuNxbme-WS+140 b1351%-971.18300
Tranche Comments
2 kp: Comments: DTX300q gh-zghl sfk 0.15% 2kg. Yee2/YYY. YNJJ/YUHB/Yegg/DR/TRYD/Hso. Zlszeggs HR+89.5 egse / 0.15% kvq, vpk 0.125% ghlkhg/kvq.; 6 vh: Comments: KWL350x jg-kqgp 0.5% 6eq. Rnn2/RRR. RVZZ/RWEC/Rnqg/KL/WLRK/Eae. Wuahnjgb EL+110 nqbn / 0.5% eex, aajnk +105. VRZ eghne.; 9 dj: Comments: HYH350o sk-xskb 1.125% 9vs. Vhh2/VVV. VWDD/VNQZ/Vhss/HC/YCVH/Qhh. Pshohsse QC+140 hseh / 1.125% vwo, ghshl +135. XVD wkohv.;
Guarantor(s)
Zwva Tmajpafwupffax Dfjumpjfwm Xfpfpwj

Commentary 

Upgrade Plan

Deal Flow 

Upgrade Plan

B&I

BWICS & Inventory

This module is available on the Professional plan. Learn moreUpgrade Plan

TRACE

This module is available on the Professional plan. Learn moreUpgrade Plan

Research